A novel electrochemical lung cancer biomarker cytokeratin 19 fragment antigen 21-1 immunosensor based on Si3N4/MoS2 incorporated MWCNTs and core–shell type magnetic nanoparticles†
Abstract
Lung cancer is one of deadliest and most life threatening cancer types. Cytokeratin 19 fragment antigen 21-1 (CYFRA 21-1) is a significant biomarker for the diagnosis of non-small cell lung cancer (NSCLC). Due to these reasons, a novel electrochemical immunosensor based on a silicon nitride (Si3N4)–molybdenum disulfide (MoS2) composite on multi-walled carbon nanotubes (Si3N4/MoS2–MWCNTs) as an electrochemical sensor platform and core–shell type magnetic mesoporous silica nanoparticles@gold nanoparticles (MMSNs@AuNPs) as a signal amplifier was presented for CYFRA21-1 detection in this study. Capture antibody (Ab1) immobilization on a Si3N4/MoS2–MWCNT modified glassy carbon electrode (Si3N4/MoS2–MWCNTs/GCE) was firstly successfully performed by stable electrostatic/ionic interactions between the –NH2 groups of the capture antibody and the polar groups of Si3N4/MoS2. Then, specific antibody–antigen interactions between the electrochemical sensor platform and the signal amplifier formed a novel voltammetric CYFRA21-1 immunosensor. The prepared composite materials and electrochemical sensor surfaces were characterized by transmission electron microscopy (TEM), scanning electron microscopy (SEM), X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), Fourier transform infrared spectroscopy (FTIR), cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS). A linearity range of 0.01–1.0 pg mL−1 and a low detection limit (LOD) of 2.00 fg mL−1 were also obtained for analytical applications. Thus, the proposed immunosensor based on Si3N4/MoS2–MWCNTs and MMSNs@AuNPs has great potential for medical diagnosis of lung cancer.
- This article is part of the themed collection: Nanoscale and Nanoscale Horizons: Nanobiotechnology and Nanomedicine